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Abstract
Introduction: Comparison studies between different analytical methodologies for circulating tumor cells (CTC)
detection and molecular characterization are urgently needed, since standardization of assays is essential before
their use in clinical practice.
Methods: We compared three different CTC molecular assays. To avoid discrepancies due to pre-analytical errors
we used the same cDNAs throughout our study. CTC were isolated using anti-EpCAM and anti-MUC1 coated
magnetic beads from 2 × 5 ml of peripheral blood of 254 early and 51 metastatic breast cancer patients and 30
healthy individuals. The same cDNAs were analyzed by: a) singleplex RT-qPCR assay for CK-19; b) multiplex RT-qPCR
for CK-19, HER-2, MAGE- A3, and PBGD; and c) a commercially available molecular assay (AdnaTest BreastCancer) for
GA733-2, MUC-1, HER-2 and beta-actin.
Results: In early breast cancer, CK-19 RT-qPCR, multiplex RT-qPCR and the AdnaTest, were positive for the presence
of CTC in 14.2%, 22.8% and 16.5% subjects, respectively. The concordance between the AdnaTest and CK-19 RT-
qPCR was 72.4% while between the AdnaTest and multiplex RT-qPCR was 64.6%. In patients with overt metastasis,
CK-19 RT-qPCR, multiplex RT-qPCR and the AdnaTest were positive in 41.2%, 39.2% and 54.9% patients, respectively.
The concordance between the AdnaTest and CK-19 RT-qPCR was 70.6% while between the AdnaTest and multiplex
RT-qPCR was 68.6%.
Conclusions: All CTC assays gave similar results in about 70% of cases. Better agreement was found in the
metastatic setting, possibly explained by the higher tumor load in this group. Discordances could be attributed to
the different gene transcripts used to evaluate CTC positivity. Our results indicate the importance of CTC
heterogeneity for their detection by different analytical methodologies.
Introduction
Βlood testing for circulating tumor cells (CTC) has
emerged as one of the hottest fields in cancer biomar-
kers research [1]. CTC enumeration is regarded as an
early marker of response to systemic therapy and can be
used as a liquid biopsy for repeated follow up examina-
tions [2], while their molecular characterization could
be translated to personalized targeted treatments [3,4].
CTC detection can give early information on relapse
and disease progression [5-9], while individualized
treatment strategies based on the molecular characteri-
zation of CTC could improve efficacy [10] and can pre-
dict early response to therapy [2,11]. There is increasing
evidence of the potential benefits of using CTC detec-
tion in clinical practice, and until now more than 400
clinical studies have included CTC as a biomarker in
various types of solid cancers.
Since CTC are found in very low frequency within the
human bloodstream their reliable isolation and detection
demands methodologies with high sensitivity and speci-
ficity. In recent years a variety of commercially available
assays have been developed to detect CTC, including
the US Food and Drug Administration (FDA)-cleared
CellSearch®system (Veridex, Raritan, NJ, USA) [12-15],
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while new areas of research are directed towards devel-
oping novel assays for CTC molecular characterization.
Molecular assays for the detection and molecular
characterization of CTC are very suitable for routine
applications in the clinical laboratory setting, provided
that they are robust and specific. Molecular assays are
highly sensitive, easy to perform, detect viable CTC,
have the advantage of in silico design, and can be easily
automated and subjected to internal and external quality
control systems. Another major advantage of molecular
assays for CTC detection is the flexibility they offer,
especially in a multiplex format, where we can signifi-
cantly reduce the amount of precious CTC sample, as
well as the time and cost of analysis. Several mRNA
markers have been used for RT-PCR-based detection of
CTC. Quantification of these mRNAs is essential to dis-
tinguish normal expression in blood from that due to
the presence of CTC. Few molecular markers provide
adequate sensitivity individually, but combinations of
markers may offer better sensitivity for CTC detection.
The first identification of distinct molecular profiles of
CTC has shown that detection of the expression of dif-
ferent genes can increase the CTC positivity of breast
cancer patients and provide additional information con-
cerning the clinical management of patients [16]. Since
then a variety of multiplex RT-PCR assays for the mole-
cular characterization of CTC have been developed, all
targeting different mRNA transcripts [17-21]. Molecular
profiling of low numbers of CTC, in positively immune-
magnetically selected CTC [21-23] or even in a high
background of leukocytes [18] is now feasible and shows
promise for further studies on the clinical relevance of
their molecular characterization. Molecular profiling of
CTC at the single cell level has also been reported [24].
Recently our group developed a multiplex RT-qPCR
assay for the quantification of CK-19, HER-2, MAGE-A3
and PBGD transcripts in early and metastatic breast
cancer patients [21]. Another molecular assay, that is
also commercially available, the AdnaTest BreastCan-
cer™ (Alere, San Diego, CA, USA) is based on the isola-
tion of CTC by immunomagnetic beads labeled with
antibodies against MUC-1 and epithelial cell adhesion
molecule (EpCAM), followed by multiplex RT-PCR for
GA 733-2, MUC1, HER-2 and beta actin [11,25].
However, the existence of numerous technical approaches
for enumeration and molecular characterization of CTC
make the assessment of CTC as a routine procedure for the
clinical management of breast cancer patients very compli-
cated. Many questions still remain unanswered regarding
the optimal method to enumerate and characterize CTC
and the path to regulatory and general clinical acceptance
of technology platforms currently under development [26].
Despite the numerous methods for CTC detection a major
question that arises is whether these assays give the same
information when analyzing the same clinical samples.
Standardization of assays used for the detection of CTC
is essential before their use in clinical practice. Towards
this direction, comparison studies between different analy-
tical methodologies for CTC detection and molecular
characterization are urgently needed [27-29]. So far, com-
parison studies have revealed distinct variations in the
detection rates for the presence of CTC between different
analytical platforms [13]. Many research groups have com-
pared the FDA-cleared CellSearch platform with other
CTC detection systems [27,30,31] and have shown discre-
pancies, possibly explained by the different approaches
used for capturing and analyzing CTC.
The aim of our study was to compare three different
molecular assays for the detection and molecular charac-
terization of CTC in primary and metastatic breast cancer:
a) a RT-qPCR assay that detects CTC through the expres-
sion of CK-19 [32]; b) a multiplex RT-qPCR assay that
detects CTC through the expression of CK-19, HER-2,
MAGE-A3, and PBGD [21]; and c) a commercially avail-
able molecular assay (AdnaTest BreastCancer™) that
detects CTC through the expression of GA733-2, MUC-1,
HER-2 and beta actin [22]. Our main question was
whether these molecular assays give comparable results
for the same samples in terms of CTC positivity or nega-
tivity, based on the fact that the molecular markers
selected are different. In order to get a more precise com-
parison, we performed our study using the same cDNAs,
to exclude all errors in the pre-analytic variables, such as
sample isolation, sample volume, logistics and storage con-
ditions, as well as important analytical variables, such as




In total, 254 patients with operable breast cancer and 51
patients with verified metastasis were enrolled in the
study. All patient samples were collected at the Depart-
ment of Obstetrics and Gynecology in the University
Hospital of Essen, Germany. Patients with primary breast
cancer were enrolled from March 2007 until March 2009.
Characteristics for primary breast cancer patients at the
time of diagnosis are shown in Table 1. The majority of
patients had small tumors and 51% were node-negative.
Most patients had ductal breast cancer. Moderately and
poorly differentiated tumors were predominant. A total of
179 of 254 (70%) patients were estrogen receptor (ER)-
positive and 175 of 254 (69%) patients were progesterone
receptor (PR)-positive. Human epidermal growth factor
receptor 2 (HER2) expression was present in 38 of 254
patients (15%). Patients with metastatic breast cancer were
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enrolled from November 2006 until October 2009. The
patient eligibility criteria were as follows: age ≥18 years;
measurable or evaluable metastatic breast cancer; pre-
dicted life expectancy ≥2 months; Eastern Cooperative
Oncology Group (ECOG) scores for performance status of
0 to 2; no severe uncontrolled co-morbidities or medical
conditions; and no second malignancies. Patients had
either a relapse of breast cancer diagnosed years before
and were to start chemotherapy or a documented progres-
sive breast cancer before receiving a new endocrine,
chemo- or experimental therapy. Prior adjuvant treatment,
radiation or any other treatment of metastatic disease
were permitted. Exclusion criteria were other malignancies
except breast cancer. Most patients had visceral and non-
visceral metastasis. The chemotherapeutic adjuvant treat-
ment mostly contained anthracyclines and taxanes.
Table 1 CTC detection and clinical characteristics of early breast cancer patients
















254 (100) 42 (16.5) 212 (83.5) 36 (14.2) 218 (85.8) 58 (22.8) 196 (77.2)
Age, years 0.398 0.383 0.614
≥ 61 130 (51.2) 24 (18.5) 106 (81.5) 16 (12.3) 114 (87.7) 28 (21.5) 102 (78.5)
< 61 124 (48.8) 18 (14.5) 106 (85.5) 20 (16.1) 104 (83.9) 30 (24.2) 94 (75.8)
Staging 0.827 0.343
Tx 1 (0.39) 0 (0) 1 (100) 0 (0) 1 (100) 0 (0) 1 (100)
is 8 (3.15) 2 (25.0) 6 (75.2) 0 (0) 8 (100) 1 (12.5) 7 (87.5)
To 6 (2.36) 1 (16.7) 5 (83.3) 0 (0) 6 (100) 2 (33.3) 4 (66.7)
I/II 206 (81.1) 29 (14.1) 177 (85.9) 34 (16.5) 172 (83.5) 48 (23.3) 158 (76.7)
III/IV 19 (7.48) 4 (21.1) 15 (78.9) 1 (5.26) 18 (94.7) 4 (21.0) 15 (79.0)
Unknown 14 (5.51)
Grading 0.386 0.822
1 45 (17.7) 5 (11.1) 40 (88.9) 6 (13.3) 39 (86.7) 12 (26.7) 33 (73.3) 0.816
2 105 (41.3) 19 (18.1) 86 (81.9) 17 (16.2) 88 (83.8) 23 (21.9) 82 (78.1)
3 83 (32.7) 10 (12.1) 73 (88.0) 11 (13.2) 72 (86.8) 19 (22.9) 64 (77.1)
Unknown 21 (8.37)
Lymph nodes
N0 130 (51.2) 17 (13.1) 113 (86.9) 0.099 23 (17.7) 107 (82.3) 0.450 31 (23.8) 99 (76.2) 0.871
N1 54 (21.3) 9 (16.7) 45 (83.3) 6 (11.1) 48 (88.9) 15 (27.8) 39 (72.2)
N2 15 (5.91) 3 (20.0) 12 (80.0) 2 (13.3) 13 (86.7) 3 (20.0) 12 (80.0)
N3 6 (2.36) 3 (50.0) 3 (50.0) 2 (33.3) 4 (66.7) 1 (16.7) 5 (83.3)
Unknown 49 (19.3)
Histology
Ductal 175 (68.9) 23 (13.1) 152 (86.9) 0.251 23 (13.1) 152 (86.9) 0.201 39 (22.3) 136 (77.7)
Lobular 35 (13.8) 7 (20.0) 28 (80.0) 9 (25.7) 26 (74.3) 12 (34.3) 23 (65.7)
Ductal/Lobular 5 (1.97) 2 (40.0) 3 (60.0) 1 (20.0) 4 (80.0) 0 (0) 5 (100)
Other 24 (9.45) 5 (20.8) 19 (79.2) 2 (8.3) 22 (91.7) 4 (16.7) 20 (83.3)
Unknown 15 (5.91)
ER 0.553 0.275 0.581
Positive 179 (70.5) 28 (15.6) 151 (84.4) 29 (16.2) 150 (83.8) 40 (22.3) 139 (77.7)
Negative 58 (22.8) 11 (19.0) 47 (81.0) 6 (10.3) 52 (89.7) 15 (25.9) 43 (74.1)
Unknown 17 (6.7)
PR 0.474 0.184 0.361
Positive 175 (68.9) 27 (15.4) 148 (84.6) 29 (16.6) 146 (83.4) 38 (21.7) 137 (78.3)
Negative 62 (24.4) 12 (19.4) 50 (80.6) 6 (9.7) 56 (90.3) 17 (27.4) 45 (72.6)
Unknown 17 (6.7)
HER2 0.725 0.397
Positive 38 (15.0) 7 (18.4) 31 (81.6) 0.639 5 (13.2) 33 (86.8) 11 (29.0) 27 (71.0)
Negative 195 (76.8) 30 (15.4) 165 (84.6) 30 (15.4) 165 (84.6) 44 (22.6) 151 (77.4)
Unknown 21 (8.27)
aChi-square test. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.
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Patients with metastatic tumors of the breast received dif-
ferent chemotherapeutic treatments including anthracy-
clines, taxane, vinorelbine and 5-fluorouracil (5-FU). Most
patients were extensively pre-treated before starting the
collection of the blood samples. Nearly all patients with
HER2 3+ tumors received trastuzumab in the metastatic
setting. A group of 30 healthy female blood donors was
used as control. All specimens were obtained after written
informed consent and collected using protocols approved
by the institutional review board (05/2856).
CTC isolation
Blood samples were taken from all patients and analyzed
for CTC using the commercially available AdnaTest
BreastCancer™ (Alere) kit which enables the immuno-
magnetic enrichment of tumor cells via epithelial and
tumor associated antigens. Blood (2 × 5 ml with addition
of ethylenediaminetetraacetic acid (EDTA)) was collected
for isolation of CTC using the AdnaCollect blood collec-
tion tubes (Alere), stored at 4°C and further processed
within 48 hours. Blood samples were incubated with a
ready-to-use antibody mixture (against EpCAM and
MUC1) according to the manufacturer’s instructions and
the labeled cells were extracted by a magnetic particle
concentrator as previously described [11,22,25].
RNA isolation from CTC and cDNA synthesis
Isolation of mRNA from lysed, enriched cells was per-
formed with the Dynabeads mRNA DIRECT™ Micro Kit
(Dynal, Karlsruhe, Germany) according to the manufac-
turer’s instructions. Sensiscript® Reverse Transcriptase
(QIAGEN, Hilden, Germany) was used for reverse tran-
scription because of its high sensitivity as previously
described [11,22,25]. All cDNA samples were first checked
for their quality using as control genes both beta-actin
and PBGD. Only samples that were positive for both con-
trol genes were enrolled in this study. More specifically,
we initially evaluated the quality of 541 cDNA samples,
but only 305 cDNAs were positive and further used. All
these samples were collected and analyzed immediately by
the AdnaTest BreastCancer™ kit. However, many cDNAs,
that we would have liked to use for CK-19 RT-qPCR and
multiplex RT-qPCR were found to be degraded and of
very pure quality. This is mainly due to the long time that
these cDNA samples were kept at -20°C (for more than
two years).
CTC detection and molecular characterization
CK-19 RT-qPCR
A singleplex RT-qPCR was performed for CK-19 in the
LightCycler 1.5 (Roche, Mannheim, Germany) as pre-
viously described [32]. The amplification reaction mixture
contained 2 μL of the PCR Synthesis Buffer (5Χ), 1 μL of
MgCl2 (25 mM), 0.2 μL dNTPs (10 mM), 0.15 μL BSA
(10 μg/μL), 0.1 μL Hot Start DNA polymerase (HotStart,
5 U/μL, Promega, Madison, USA), 0.5 μL of each primer
(10 μΜ), 1.0 μL of each hydrolysis probe (3 μM) and ster-
ile H2O (added to 10 μL final volume). Cycling conditions
were: 95°C for 3 minutes; 45 cycles of 95°C for10 seconds,
annealing at 55°C for 20 seconds and extension at 72°C for
20 seconds.
Multiplex RT-qPCR
Multiplex RT-qPCR was performed for CK-19, HER-2,
MAGE-A3 and PBGD was used as control gene as pre-
viously described [21]. Multiplex RT-qPCR reactions
were performed in the LightCycler 2.0 (Roche). The
amplification reaction mixture contained 2 μL of the
PCR Synthesis Buffer (5Χ), 2.5 μL of MgCl2 (25 mM),
0.4 μL dNTPs (10 mM), 0.8 μL BSA (10 μg/μL), 0.4 μL
Hot Start DNA polymerase (HotStart, 5 U/μL, Pro-
mega), 1 μL of all eight primers (10 μΜ for each),
0.5 μL of all eight dual hybridization probes (4 μM for
each) and sterile H2O (added to 10 μL final volume).
Cycling conditions were: 95°C for 3 minutes; 45 cycles
at 95°C for 10 seconds, annealing at 60°C for 60 seconds
and extension at 72°C for 30 seconds.
AdnaTest BreastCancerDetect
The AdnaTest BreastCancerDetect kit was used for the
detection of HER-2, MUC1 and GA733-2 (EpCAM) in all
cDNAS. PCR was performed with the HotStarTaq Master
Mix (QIAGEN). Beta-actin was used as control gene. The
thermal profile used was as follows: After a 15 minute
denaturation at 95°C, 35 cycles of PCR were carried out by
denaturation at 94°C for 60 seconds, annealing/extension
at 60°C for 60 seconds and elongation for 60 seconds at
72°C. Subsequently, termination of the reaction was car-
ried out at 72°C for 10 minutes followed by storage of the
samples at 4°C. The primers generated fragments of the
following sizes: GA733-2:395 bp, MUC1:293 bp, HER-
2:270 bp, and b-actin:114 bp. Visualization of PCR frag-
ments was carried out with a 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA) using the DNA 1000
LabChips and the Expert Software Package (version
B.02.03.SI307). The test was considered as CTC positive if
a PCR fragment of at least one tumor-associated transcript
(MUC-1, GA773-2 or HER-2) and a fragment of b-actin
was clearly detected (peak concentration of > 15 ng/ul) in
both blood samples. According to previous studies, this
assay is highly sensitive as it can detect two cells per 5 ml
of blood, and highly specific (95%) [11,22,25].
Statistical analysis
The chi square test was used for the evaluation of concor-
dance in the early breast cancer setting while in the veri-
fied metastasis group, where a lower number of cases was
studied, we performed the Fischer’s exact test. We have
also used the Kappa test in all cases to evaluate the agree-
ment between these molecular methods [33].
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The outline of the whole experimental design is given
in Additional file 1 as a figure.
Results
CK-19 RT-qPCR
This assay has already been analytically validated in detail
in our previous studies [6,32] and has been shown to give
results of clinical significance when applied in early breast
cancer and CTC were isolated from 20 mL peripheral
blood [7,8,32]. In the present study, in the group of early
breast cancer patients, CTC were isolated according to the
AdnaTest BreastCancer™ system from 2 × 5 mL periph-
eral blood and detected in 36/254 patients by CK-19 RT-
qPCR (14.2%), while in the group of 51 patients with overt
metastasis, CTC were detected in 21 patients (41.2%)
(Table 2). In the group of 30 healthy individuals tested,
one was found positive for CK-19 (3.3%).
Multiplex RT-qPCR
This assay has also been analytically validated in detail in
our previous study where CTC were also isolated from
20 mL peripheral blood [21]. The multiplex RT-qPCR was
considered positive if a PCR fragment of at least one
tumor-associated transcript (CK-19, MAGE-A3 and HER-
2) was detected. In the present study, in the group of early
breast cancer patients, CTC were isolated according to the
AdnaTest BreastCancer™ system from 2 × 5 mL periph-
eral blood and were detected in 58/254 (22.8%) by multi-
plex RT-qPCR (Table 2). As can be seen in Table 3,
CK-19 was positive in 25/254 (9.8%), MAGE- A3 in 12/
254 (4.7%) and HER-2 in 28/254 (11.0%) patients. In the
group of patients with verified metastasis, CTC were
detected in 20/51 (39.2%) (Table 2) with positive expres-
sion rates of 18/51 (35.3%) for CK-19, of 4/51 (7.8%) for
MAGE-A3 and 8/51 (15.7%) for HER-2 (Table 3). In a
total of 30 healthy individuals tested, 6.6% were found to
be positive by the multiplex RT-qPCR for CK-19, HER-2,
MAGE-A3 and PBGD.
AdnaTest BreastCancer™
The AdnaTest BreastCancer™ assay is considered positive
if a PCR fragment of at least one transcript is detected at a
concentration of 0.15 ng/μl or higher. Using these criteria,
all 30 healthy individuals tested were found to be negative,
while in the group of early breast cancer patients, CTC
were detected in 42/254 patients (16.5%) (Table 2) with
the positive expression rates of 3.5% for GA733-2, 5.5% for
MUC-1 and 10.2% for HER-2 (Table 3). In the group of
patients with verified metastasis, CTC were detected in
28/51 patients (54.9%) (Table 2), with GA733-2 detected
in 20/51 (39.2%), MUC-1 in 23/51 (45.1%) and HER-2 in
18/51(35.3%) patients (Table 3).
Comparison between the three molecular assays for
CTC detection
When the same target (CK-19) was detected in the same
cDNAs with the same set of primers and probes there was
a very good concordance between singleplex RT-qPCR
and multiplex RT-qPCR. In early breast cancer, where the
number of CTC and thus the number of mRNA tran-
scripts are very low, we found a concordance for 223/254
(87.8%, P = 0.000) of all samples tested while in the veri-
fied metastasis setting the concordance was almost perfect,
for 48/51 (94.1%, P = 0.000) of all samples tested (Table 4).
In early breast cancer, we found an agreement between
the AdnaTest BreastCancer™ and CK-19 RT-qPCR in
184/254 (72.4%) of the cases. However, the correlation
concerning the CTC positivity between these two assays
Table 2 Comparison between CK19 RT-qPCR, multiplex RT-qPCR and AdnaTest for the detection of CTC in breast
cancer
Molecular assay CK19 RT-qPCR Multiplex- RT-qPCR Total
Early breast cancer, (number = 254)
AdnaTest Positive Negative Positive Negative Total (%)
Positive 4 38 5 37 42 (16.5)
Negative 32 180 53 159 212 (83.5)
Total (%) 36 (14.2) 218 (85.8) 58 (22.8) 196 (77.2) 254
Kappa test poor agreement: Kappa = -0.059 (P = 0.344) poor agreement: Kapp = -0.114 (P = 0.065)
Concordance (%) 184 (72.4), Pa = 0.344 164 (64.6), Pa = 0.065
Verified metastasis, (number = 51)
AdnaTest Positive Negative Positive Negative Total (%)
Positive 17 11 16 12 28 (54.9)
Negative 4 19 4 19 23 (45.1)
Total (%) 21 (41.2) 30 (58.8) 20 (39.2) 31 (60.8) 51
Kappa test Moderate agreement: Kappa = 0.422 (P = 0.002), Fair agreement: Kappa = 0.386 (P = 0.004)
Concordance (%) 36 (70.6), Pa = 0.002 35 (68.6), Pa = 0.004
achi-square test, kappa test; 95% CI (0.504, 0.848). The same result was found when we used the chi-square test (Table 2).
Strati et al. Breast Cancer Research 2013, 15:R20
http://breast-cancer-research.com/content/15/2/R20
Page 5 of 11
was not significant (P = 0.344), since there were 32 sam-
ples that were found positive for CTC by the CK-19 assay
but negative by the AdnaTest and 38 samples found posi-
tive for CTC by the AdnaTest but negative by the CK-19
assay. The concordance between the AdnaTest and multi-
plex RT-qPCR in this group of patients was 64.6%. There
was no significant correlation (P = 0.065) in this case as
well, since there were 53 samples found positive for CTC
by the multiplex RT-qPCR assay but negative by the
AdnaTest and 37 samples found positive for CTC by the
AdnaTest but negative by the multiplex RT-qPCR assay
(Table 2). In this group, all combinations found for each
molecular target are shown in Figure 1.
In the group of patients with verified metastasis, we
found an agreement between the AdnaTest and CK-19
RT-qPCR in 36/51 (70.6%) of cases. The correlation con-
cerning the CTC positivity between these two assays was
significant (P = 0.002), since there were only four samples
that were found positive for CTC by the CK-19 assay but
negative by the AdnaTest and 11 samples found positive
for CTC by the AdnaTest but negative by the CK-19 RT-
qPCR. In all other cases these two assays gave similar
results. Between the AdnaTest and multiplex RT-qPCR,
the concordance rate in the group of patients with veri-
fied metastasis was 68.6%. There was a significant corre-
lation (P = 0.004) in this case as well, since there were
Table 3 Comparison between CK19 RT-qPCR, multiplex RT-qPCR and AdnaTest for the molecular characterization of
CTC in breast cancer.
Multiplex RT-qPCR Singleplex RT-qPCR
AdnaTest/ CK19 HER-2 MAGE A3 CK19
Pos. Neg. Pos. Neg. Pos. Neg. Pos. Neg.
Early breast cancer, (number = 254)
GA733-2 Positive 1 8 0 9 0 9 2 7
Negative 24 221 28 217 12 233 34 211
Concordance (%) 87.4 Pa = 0.897 85.4 Pa = 0.284 91.7 Pa = 0.496 83.9 Pa = 0.481
MUC-1 Positive 0 14 1 13 0 14 1 13
Negative 24 215 27 213 12 228 35 205
Concordance (%) 84.6 Pa = 0.213 84.3 Pa = 0.633 89.8 Pa = 0.391 81.1 Pa = 0.438
HER-2 Positive 2 24 2 24 0 26 2 24
Negative 23 205 26 202 12 216 34 194
Concordance (%) 81.5 Pa = 0.698 80.3 Pa = 0.567 85 Pa = 0.231 77.2 Pa = 0.317
Verified metastasis, (number = 51)
GA733-2 Positive 14 6 6 14 3 17 15 5
Negative 4 27 2 29 1 30 6 25
Concordance (%) 80.4 Pb < 0.001 68.6 Pb = 0.045 64.7 Pb = 0.287 78.4 Pb = 0.000
MUC-1 Positive 14 9 6 17 3 20 14 9
Negative 4 24 2 26 1 27 7 21
Concordance (%) 74.5 Pb = 0.001 62.7 Pb = 0.119 58.8 Pb = 0.316 68.6 Pb = 0.012
HER-2 Positive 11 7 5 13 1 17 13 5
Negative 7 26 3 30 3 30 8 25
Concordance (%) 72.6 Pb = 0.006 68.6 Pb = 0.112 60.8 Pb = 1 74.5 Pb = 0.001
achi-square test; bFisher’s exact test; P < 0.05 is considered as significant.
Table 4 Comparison between CK-19 RT-qPCR, and multiplex RT-qPCR for CK-19 detection
Molecular assay CK-19 RT-qPCR
CK-19 multiplex RT-qPCR Early breast cancer, (number = 254) Verified metastasis, (number = 51)
Positive Negative Positive Negative
Positive 15 10 18 0
Negative 21 208 3 30
Total (%) 36 (14.2) 218 (85.8) 21 (41.2) 30 (58.8)
Kappa test Moderate agreement: Kappa = 0.425 (P = 0.000) Pa = 0.000P = = Pp(P
= 0.000)
Almost perfect agreement: Kappa = 0.876 (P =
0.000)
Concordance (%) 223 (87.8), Pa = 0.000 48 (94.1), Pa = 0.000
aChi-square test.
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only four samples that were found positive for CTC by
the multiplex RT-qPCR but negative by the AdnaTest
and 12 samples found positive by the AdnaTest but nega-
tive by the multiplex RT-qPCR (Table 2). In all the other
cases, these two assays gave similar results as well. In this
group, the comparison results for each individual sample
are shown in a heatmap (Figure 2).
Comparison of AdnaTest BreastCancer™ and multiplex
RT-qPCR for HER-2 expression in CTC
HER-2 is the only common target between the AdnaT-
est BreastCancer™ and multiplex RT-qPCR; however,
different primers targeting completely different sequence
areas are used by these two molecular assays for evalu-
ating HER-2 expression.
Early breast cancer patient (n=254) 
Molecular 
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Figure 1 Molecular profiling of CTC in early breast cancer (n = 254). Red and green indicates positive and negative detection, respectively.
Strati et al. Breast Cancer Research 2013, 15:R20
http://breast-cancer-research.com/content/15/2/R20
Page 7 of 11
Concerning HER-2 expression in CTC there was no sig-
nificant correlation (P = 0.567) between multiplex RT-
qPCR and the AdnaTest, since there were 26 samples that
were found positive for HER-2 in CTC by the multiplex
RT-qPCR assay but negative by the AdnaTest and 24 sam-
ples found positive for HER-2 in CTC by the AdnaTest
but negative by the multiplex RT-qPCR (Table 3). As can
be seen in Table 3, in the early breast cancer group, there
were only two samples that were found positive for HER-2
in CTC both by the multiplex RT-qPCR and by the
AdnaTest, while 202 samples were found negative by both
assays.
In the group of patients with verified metastasis (Table 3),
there were only five samples found to be positive for HER-2
in CTC, both by the multiplex RT-qPCR and by the
AdnaTest, while 30 samples were found to be negative by
both assays. There was no significant correlation (P =
0.112), since three samples were found positive for HER-2
in CTC by the multiplex RT-qPCR but negative by the
AdnaTest and 13 samples were found positive for HER-2 in
CTC by the AdnaTest but negative by the multiplex RT-
qPCR. HER-2 comparison results for each individual sam-
ple can be seen in Figure 2.
We also had the information on HER-2 expression in
the primary tumors for 233 of these samples. The AdnaT-
est detected HER-2 expression in CTC in 24 patients, but
HER-2 status of the primary tumor was positive and con-
cordant in only four patients, negative and discordant in
20, while in 175 cases HER-2 expression was not detected
in either the primary tumor or in CTC. The multiplex RT-
qPCR detected HER-2 expression in CTC in 27 patients,
but HER-2 status of the primary tumor was positive in
only six of these patients, negative and discordant in 21,
while in 174 cases HER-2 expression was not detected in
either primary tumor or in CTC (Additional file 2).
Discussion
Quality control is an important issue for the clinical use
of CTC analysis, and standardization of CTC detection
and characterization methodologies are important for the
incorporation of CTC into prospective clinical trials test-
ing their clinical utility [26]. Moreover, the analytical
assays used and the degree of their validation will be cri-
tical to establishing a common set of criteria describing
CTC [26]. Despite the fact that most CTC assays are
highly specific and sensitive, there are not so many exten-
sive studies especially designed to compare their efficacy
when using the same clinical samples. This is an impor-
tant issue for their clinical use since, especially in early
disease, differences in analytical sensitivity between CTC
assays play a very critical role. Among the recommenda-
tions described in a recent report by the AACR-FDA-
NCI Cancer Biomarkers Collaborative, inter-laboratory
and intra-laboratory comparison studies for the same
samples are urgently needed [34].
So far, the main technology where quality control issues
have been addressed in the field of CTC assays is the Cell-
Search [27,30,35,36]. In a recent comparison study
between the CellSearch and AdnaTest BreastCancer™
assays, concordant results regarding HER-2 positivity were
obtained only in 50% of the patients [37]. Another recent
study directly compared three techniques for detecting
CTC in blood samples: the CellSearch, the AdnaTest
BreastCancer™ and an in-house RT-qPCR assay and
found a substantial variation in the detection rates of CTC
in blood from breast cancer patients [38]. The results of
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Figure 2 Molecular profiling of CTC in verified metastasis (n = 51). Red and green indicates positive and negative detection, respectively.
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the DETECT trial which was designed to compare directly
the prognostic value of two commercially available CTC
assays in metastatic breast cancer have shown that the
prognostic relevance of CTC detection depends on the
test method, and that the CellSearch assay is superior to
the AdnaTest BreastCancer™ assay in predicting clinical
outcome [39]. However, another study has revealed that
the AdnaTest BreastCancer™ has equivalent sensitivity to
that of the CellSearch in detecting two or more CTC [40].
Moreover, recent studies, especially in early breast cancer,
have also shown a superior sensitivity of molecular assays
with respect to the CellSearch [11,21,25,28]. In most of
these comparison studies, discrepancies found between
the different assays were partly explained by the fact that
these molecular assays were using different capture tech-
nologies for CTC isolation and very different detection
systems.
In the present study, we compared three molecular
assays for the detection and molecular characterization
of CTC after excluding all errors in the pre-analytic
variables, such as sample isolation, sample volume, logis-
tics and storage conditions, as well as important analytic
variables, such as CTC isolation methodology, RNA iso-
lation, and cDNA preparation steps [26]. In this way, we
evaluated the effect of using different molecular tran-
scripts on CTC detection.
When the same target (CK-19) was detected in the
same cDNAs with the same set of primers and probes
there was a very good concordance between singleplex
RT-qPCR and multiplex RT-qPCR. Slight discrepancies
in this case could possibly reflect differences in the
probability of finding mRNA transcripts in these sam-
ples due to the very low expected CTC numbers (Pois-
son distribution).
When the same target (HER-2) was detected in the same
cDNAs with a different set of primers, targeting different
regions in the gene sequence, and by different detection
systems, results were not statistically correlated. However,
there was a concordance between findings for 80.3% of
cases in early breast cancer and 68.6% of cases in patients
with verified metastasis. In both cases the majority of the
samples were found to be negative by both primers sets
(79.5% in early and 58.8% in metastasis). There were dis-
crepancies in 19.7% of early and 31.4% of metastasis cases,
while a very small number of samples were found to be
positive by both primer sets (Table 3). When the presence
of CTC positivity was assessed based on completely differ-
ent transcripts, as in the case of singleplex RT-qPCR for
CK-19 versus AdnaTest BreastCancer™, or multiplex RT-
qPCR versus AdnaTest BreastCancer™, there were discre-
pancies when the number of CTC was low, as in early
breast cancer. On the contrary, in cases where the number
of CTC was higher, as in verified metastasis, these assays
gave comparable results even while targeting different
transcripts. Especially CK-19 expression was significantly
correlated in all cases when compared to transcripts
detected by the AdnaTest BreastCancer™ (Table 3).
We now know that CTC are highly heterogeneous even
in the same patient [24]. Based on this, we could possibly
explain the discrepancies found between these molecular
assays by the fact that they are targeting different gene
transcripts in CTC. In this way these assays can give the
same result for the presence or absence of CTC in a clini-
cal sample, only in the case that all these targets are
simultaneously present or absent in a sample. Another
explanation for the lack of statistical correlation in early
breast cancer could possibly be the very low tumor load
in this case. In verified metastasis, where there is a higher
tumor load, a statistical agreement was verified between
these assays, and CK-19 expression correlated with HER-
2, GA733-2 and MUC-1. According to our data, in early
breast cancer the same cDNA samples could be consid-
ered positive for the presence of CTC by one molecular
assay and negative by the other. This is, however, very
critical, especially when important clinical decisions are
going to be based on this information, such as the admin-
istration of trastuzumab [10]. It is also obvious that much
higher discrepancies are expected when different blood
volumes and different isolation systems for CTC are
used.
As an example, the immunoselection procedure fol-
lowed in this work (since we are handling samples isolated
by the AdnaTest) has modified the CTC positivity as
based on our previously reported CK-19 assay that is not
using any immunoselection [6-8,10,32]. There is no doubt
that a different population of cells is isolated by using
these different procedures. It is completely different to
analyze only EpCAM- and MUC1-positive cells with
respect to a highly sensitive CK-19 detection among all
peripheral blood mononuclear cells (PBMCs) without any
influence of the EpCAM expression on these cells. More-
over, in our already published protocol without immuno-
selection we are using 20 mL of peripheral blood for CTC
isolation in the adjuvant setting [6,32], whereas in this
case we are using cDNAs from EpCAM-positive CTC iso-
lated from 2 × 5 mL peripheral blood. This could also
explain the lower rates in CK-19 positivity seen in this
sample cohort, in respect to the positive rates that we have
previously reported. This could be evaluated in a future
study, where the same peripheral blood samples from a
significant number of patients could be analyzed by these
molecular assays starting from the CTC isolation step and
not from the cDNA step, adding an extra level of
variability.
Recent genetic analyses of paired samples from primary
tumors and disseminated tumor cells have uncovered a
bewildering genetic disparity, questioning the use of pri-
mary tumors as surrogates for the genetics of systemic
Strati et al. Breast Cancer Research 2013, 15:R20
http://breast-cancer-research.com/content/15/2/R20
Page 9 of 11
cancer [41]. In the era of molecular therapies that build
upon genetic defects of tumor cells, these data call for a
direct diagnostic pathology of systemic cancer [41].
Towards this direction, molecular assays are high-
throughput, robust, sensitive and highly specific for the
molecular characterization of CTC. However, our data
indicate the importance of CTC heterogeneity for their
detection by different molecular assays. A universal inter-
nal and external quality control system both for CTC
detection, enumeration and molecular characterization is
urgently needed before their application in the clinic.
Moreover, the most important aspect for the multitude
of assays developed for the detection of CTC is the clini-
cal relevance of the results obtained.
Conclusions
Quality control is an important issue for the clinical use
of CTC analysis, and standardization of CTC detection
and characterization methodologies are important for the
incorporation of CTC into prospective clinical trials test-
ing their clinical utility Towards this direction, compari-
son studies between different analytical methodologies
for CTC detection and molecular characterization are
urgently needed, since standardization of assays is essen-
tial before their use in clinical practice. In the present
study we compared three molecular assays for the detec-
tion and molecular characterization of CTC after exclud-
ing all errors in the pre-analytic variables, such as sample
isolation, sample volume, logistics and storage condi-
tions, as well as important analytic variables such as the
CTC isolation methodology, RNA isolation, and cDNA
preparation steps. In this way, we evaluated the effect of
using different molecular transcripts on CTC detection.
When the same target was detected in the same cDNAs
with the same set of primers and probes there was a very
good concordance between singleplex RT-qPCR and
multiplex RT-qPCR. When the same target was detected
in the same cDNAs with a different set of primers, target-
ing different regions in the same gene sequence (HER-2),
and by different detection systems, results were not sta-
tistically correlated. When the presence of CTC positivity
was assessed based on completely different transcripts,
there were discrepancies when the number of CTC was
low, as in early breast cancer. On the contrary, in cases
where the number of CTC was higher, as in verified
metastasis, these assays gave comparable results even
while targeting different transcripts. Our data indicate
the importance of CTC heterogeneity for their detection
by different molecular assays.
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